Brought to you by 
J&J teams up with Orexo for respiratory drug development; terminated
18 Feb 2015
Executive Summary
Orexo (working on therapeutics for pain and inflammatory conditions) has licensed Johnson & Johnson's Ortho-McNeil Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica NV (collectively OMJ) global rights to its OX-CLI and OX-ESI preclinical programs for asthma, COPD, and other inflammatory diseases. OMJ will also add a third internal drug candidate to the three-year-deal.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J teams up with Orexo for respiratory drug development; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice